New study shows that chronic kidney diseases originate from bone marrow
In recent years, suPAR protein was found through recombinant mouse proteins to cause chronic kidney disease and can be used as markers of chronic kidney disease. However, it has been a mystery that which part of the human body suPAR originated so far. A study published on December 12 in the journal Nature Nature showed that immature bone marrow cell derived from bone marrow is the source of aberrantly-expressed suPAR, causing chronic kidney disease.
The soluble urokinase-type plasminogen activator receptor (su-PAR) is a soluble form of urokinase-type plasminogen activator receptor (uPAR), which exists in serum and plasma, cerebrospinal fluid, urine and other body fluids of healthy people and patients with various diseases, reflecting the body’s immune system activation level. In some infectious diseases (such as bacteremia, HIV infection) and tumors and some chronic diseases (such as kidney disease, liver disease), suPAR levels rise.
In the study, the Rush University Medical Center’s team showed that bone marrow was associated with kidney function and that they had determined that bone marrow derived an immature bone marrow cell was a source of aberrantly expressed suPAR that caused chronic kidney disease. The Reiser team focuses on a chronic kidney disease — focal segmental glomerulosclerosis (FSGS), which can destroy the kidneys and ultimately cause kidney failure in severe cases. Even after kidney transplantation, the disease is prone to recur. They used the “humanized” mouse model and peripheral blood stem cells from patients with kidney disease to send signals to immature bone marrow cells in mice. These genetically-modified animals were used to study the generation and action of suPAR as a metastatic model of human renal disease.
A high level of suPAR is found in clinical studies in patients with new kidneys (FSGS patients), and the rate of recurrence of FSGS in adults is as high as 30%. The researchers concluded that circulating suPAR may come from outside the kidney.
Early results have led researchers to focus on two hematopoietic blood cells, lymphocytes and bone marrow cells. In mice lacking lymphoid cells, the researchers found that the mice still had high levels of suPAR and proteinuria, suggesting that lymphoid cells were not a source of kidney disease. The Reiser team found that bone marrow-derived immature bone marrow cells are the main source of circulating suPAR and cause of kidney disease. SuPAR is not only a biomarker of kidney disease, but also an incentive for this disease.
Other lifestyles will affect suPAR. Smoking and weight gain will increase the level of suPAR, and bad habits will increase the risk of kidney disease. Quitting smoking and weight loss can help to reduce suPAR levels, but as with cholesterol levels, the benefits of good habits are limited. The regulation of suPAR levels may require drug intervention, but a better lifestyle will not cause suPAR to fall to perfectly normal levels.
The study identified bone marrow-derived immature myeloid cells as the primary source of suPAR that is responsible for circulating kidney disease. The researchers believe that stem cell transplantation may be a viable treatment method of suPAR-related kidney disease. Flarebio offers recombinant proteins of good quality such as recombinant Fap.